VEGFA and age-related macular degeneration: Riaz et al. performed a GWAS analysis on 285 anti-VEGF-treated AMD patients, concluding that OR52B4 rs4910623 SNP was associated with a poor VA response after 3 and 6 months of ranibizumab treatment [128].